Non-Ras targets of farnesyltransferase inhibitors: focus on Rho View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1998-09

AUTHORS

Peter F Lebowitz, George C Prendergast

ABSTRACT

Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals. More... »

PAGES

1439

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.onc.1202175

DOI

http://dx.doi.org/10.1038/sj.onc.1202175

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025114095

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9779989


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Actins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alkyl and Aryl Transferases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Adhesion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Transformed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endothelial Growth Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Farnesyltranstransferase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "GTP-Binding Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphokines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Endothelial Growth Factor A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Endothelial Growth Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ras Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "rhoB GTP-Binding Protein", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wistar Institute", 
          "id": "https://www.grid.ac/institutes/grid.251075.4", 
          "name": [
            "The Wistar Institute, Philadelphia, Pennsylvania 19104, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lebowitz", 
        "givenName": "Peter F", 
        "id": "sg:person.0645204112.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645204112.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wistar Institute", 
          "id": "https://www.grid.ac/institutes/grid.251075.4", 
          "name": [
            "The Wistar Institute, Philadelphia, Pennsylvania 19104, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prendergast", 
        "givenName": "George C", 
        "id": "sg:person.0651643165.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651643165.04"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-09", 
    "datePublishedReg": "1998-09-01", 
    "description": "Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.onc.1202175", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Non-Ras targets of farnesyltransferase inhibitors: focus on Rho", 
    "pagination": "1439", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "77a4f9ed3a6c919e3b9316677e8ebdff7fd98240e4bcac876681c6a4c41c3ce6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9779989"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8711562"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.onc.1202175"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025114095"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.onc.1202175", 
      "https://app.dimensions.ai/details/publication/pub.1025114095"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000360_0000000360/records_118309_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/1202175"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'


 

This table displays all metadata directly associated to this object as RDF triples.

148 TRIPLES      20 PREDICATES      47 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.onc.1202175 schema:about N01f203f8c9054ab4a91aeb0618ff14e7
2 N023367a4f1f049ed973ecffeca080a37
3 N07090736e23a42599fcc38c6328e03fd
4 N23b3df8ad78b492a90debf7b8db05d09
5 N2f88d52bbd624d3a8e51c5003fa8a749
6 N3b0a446caf6245bf9fcc399133d404ac
7 N65cb11979ee743749d81d95f538adfe2
8 N6a6d1b153c3642539c25f403ef51ddad
9 N7fca73d55cb646de8d71467c025ab5e8
10 N8a2cceeb9b1645cc886a138ce7463ceb
11 N986b1792646346cca23aeb0b0678d6ff
12 Nd2e7229120714e1dabfa7bfe142f9459
13 Nd7ccb6e2951b48dd8d3d5febe2684715
14 Ne29db74d03f7498980c022e590687a18
15 Nee4bba18c2ef4a2b81594a652e6c6da3
16 Nee76d6db3c0f4c3e9650c379c25088f1
17 Nfb8b37177b82423dbfdbf1b340ebd533
18 Nfc920a1e913a466389689591ce09752f
19 anzsrc-for:06
20 anzsrc-for:0601
21 schema:author N2b0db4363fde4141a0d8605b438c4f1a
22 schema:datePublished 1998-09
23 schema:datePublishedReg 1998-09-01
24 schema:description Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N5298787a4ee94ec2bfa925aadfe2babb
29 Ne06c8f4b56284db3afa0247c212f9a62
30 sg:journal.1097543
31 schema:name Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
32 schema:pagination 1439
33 schema:productId N279534d93c7048d68539ffbb609304c0
34 N32f7642c095440ab87a9f91c54abaae2
35 N351591190b054bcfb722a596c8eabbc5
36 N520e47acaab846feae87dfd6fbe7c119
37 Nbb1b83f9bd584c51a3ab751c29a5016b
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025114095
39 https://doi.org/10.1038/sj.onc.1202175
40 schema:sdDatePublished 2019-04-11T12:03
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N82e9e6ca8500473a93ab592ae0be33c0
43 schema:url https://www.nature.com/articles/1202175
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N01f203f8c9054ab4a91aeb0618ff14e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
48 schema:name Vascular Endothelial Growth Factors
49 rdf:type schema:DefinedTerm
50 N023367a4f1f049ed973ecffeca080a37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name ras Proteins
52 rdf:type schema:DefinedTerm
53 N07090736e23a42599fcc38c6328e03fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Vascular Endothelial Growth Factor A
55 rdf:type schema:DefinedTerm
56 N171ba416dbee449896e56f48f23bcde4 rdf:first sg:person.0651643165.04
57 rdf:rest rdf:nil
58 N23b3df8ad78b492a90debf7b8db05d09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Lymphokines
60 rdf:type schema:DefinedTerm
61 N279534d93c7048d68539ffbb609304c0 schema:name doi
62 schema:value 10.1038/sj.onc.1202175
63 rdf:type schema:PropertyValue
64 N2b0db4363fde4141a0d8605b438c4f1a rdf:first sg:person.0645204112.22
65 rdf:rest N171ba416dbee449896e56f48f23bcde4
66 N2f88d52bbd624d3a8e51c5003fa8a749 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Cell Adhesion
68 rdf:type schema:DefinedTerm
69 N32f7642c095440ab87a9f91c54abaae2 schema:name dimensions_id
70 schema:value pub.1025114095
71 rdf:type schema:PropertyValue
72 N351591190b054bcfb722a596c8eabbc5 schema:name nlm_unique_id
73 schema:value 8711562
74 rdf:type schema:PropertyValue
75 N3b0a446caf6245bf9fcc399133d404ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name rhoB GTP-Binding Protein
77 rdf:type schema:DefinedTerm
78 N520e47acaab846feae87dfd6fbe7c119 schema:name pubmed_id
79 schema:value 9779989
80 rdf:type schema:PropertyValue
81 N5298787a4ee94ec2bfa925aadfe2babb schema:volumeNumber 17
82 rdf:type schema:PublicationVolume
83 N65cb11979ee743749d81d95f538adfe2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name GTP-Binding Proteins
85 rdf:type schema:DefinedTerm
86 N6a6d1b153c3642539c25f403ef51ddad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Membrane Proteins
88 rdf:type schema:DefinedTerm
89 N7fca73d55cb646de8d71467c025ab5e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Cell Line, Transformed
91 rdf:type schema:DefinedTerm
92 N82e9e6ca8500473a93ab592ae0be33c0 schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 N8a2cceeb9b1645cc886a138ce7463ceb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Neoplasms
96 rdf:type schema:DefinedTerm
97 N986b1792646346cca23aeb0b0678d6ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Actins
99 rdf:type schema:DefinedTerm
100 Nbb1b83f9bd584c51a3ab751c29a5016b schema:name readcube_id
101 schema:value 77a4f9ed3a6c919e3b9316677e8ebdff7fd98240e4bcac876681c6a4c41c3ce6
102 rdf:type schema:PropertyValue
103 Nd2e7229120714e1dabfa7bfe142f9459 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antineoplastic Agents
105 rdf:type schema:DefinedTerm
106 Nd7ccb6e2951b48dd8d3d5febe2684715 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Animals
108 rdf:type schema:DefinedTerm
109 Ne06c8f4b56284db3afa0247c212f9a62 schema:issueNumber 11
110 rdf:type schema:PublicationIssue
111 Ne29db74d03f7498980c022e590687a18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Farnesyltranstransferase
113 rdf:type schema:DefinedTerm
114 Nee4bba18c2ef4a2b81594a652e6c6da3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Enzyme Inhibitors
116 rdf:type schema:DefinedTerm
117 Nee76d6db3c0f4c3e9650c379c25088f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Endothelial Growth Factors
119 rdf:type schema:DefinedTerm
120 Nfb8b37177b82423dbfdbf1b340ebd533 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 Nfc920a1e913a466389689591ce09752f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Alkyl and Aryl Transferases
125 rdf:type schema:DefinedTerm
126 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
127 schema:name Biological Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
130 schema:name Biochemistry and Cell Biology
131 rdf:type schema:DefinedTerm
132 sg:journal.1097543 schema:issn 0950-9232
133 1476-5594
134 schema:name Oncogene
135 rdf:type schema:Periodical
136 sg:person.0645204112.22 schema:affiliation https://www.grid.ac/institutes/grid.251075.4
137 schema:familyName Lebowitz
138 schema:givenName Peter F
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645204112.22
140 rdf:type schema:Person
141 sg:person.0651643165.04 schema:affiliation https://www.grid.ac/institutes/grid.251075.4
142 schema:familyName Prendergast
143 schema:givenName George C
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651643165.04
145 rdf:type schema:Person
146 https://www.grid.ac/institutes/grid.251075.4 schema:alternateName Wistar Institute
147 schema:name The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
148 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...